Greenwich LifeSciences (GLSI) said Monday it has partnered with Unicancer and its breast cancer group to activate clinical sites in France for a phase III clinical trial of the GLSI-100 immunotherapy.
The phase III study of the immunotherapy, which is being evaluated to prevent breast cancer recurrences, will be activated in 19 French sites in the UCBG breast cancer group network, the company said.
Authorities in France approved the sites in Q1 2024, Greenwich said.
Shares were down 1.7% in recent trading.
Price: 12.17, Change: -0.21, Percent Change: -1.70
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.